Suicide genes as safety switches in T lymphocytes

Cytotherapy

Volumn 5, Issue 3, 2003, Pages 227-230

  Straathof, Karin C ^a   Spencer, D M ^a   Sutton, R E ^a   Rooney, C M ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AP 1903; CANCER GROWTH FACTOR; CASPASE; CD137 LIGAND; CD20 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; FAS ANTIGEN; FK 506 BINDING PROTEIN; FLICE INHIBITORY PROTEIN; GANCICLOVIR; GENE PRODUCT; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 2; LIGAND; NERVE GROWTH FACTOR RECEPTOR; PRODRUG; PROTEIN BCL 2; RITUXIMAB; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; BONE MARROW TRANSPLANTATION; CELL BASED GENE THERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE THERAPY; GENE TRANSFER; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; INTERNAL RIBOSOME ENTRY SITE; LYMPHOPROLIFERATIVE DISEASE; MARKER GENE; MORBIDITY; MORTALITY; PROPHYLAXIS; REVIEW; SIDE EFFECT; SUICIDE GENE; SUICIDE GENE THERAPY; T LYMPHOCYTE;

EID: 0043196687     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240310001497     Document Type: Review

References (23)

1. Kolb H-J, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte infusions in marrow grafted patients. Blood 1995;86:2041-50.
2. Heslop HE, Ng CYC, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-5.
3. Bollard CM, Rossig C, Calonge MJ et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002;99:3179-87.
4. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348:255-6.
5. Spencer DM. Developments in suicide genes for preclinical and clinical applications. Curr Opin Mol Ther 2000;2:433-40.
6. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-24.
7. Tiberghien P, Ferrand C, Lioure B et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001;97:63-72.
8. Chalmers D, Ferrand C, Apperley JF et al. Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. Mol Ther 2001;4:146-8.
9. Bonini C, Ciceri F, Marktel S et al. Abrogation of GvHD and early immune reconstitution after infusion of HSV-TK engineered donor lymphocytes after haplo-identical hematopoietic stem cell transplantation. Blood 2002;100:115a.
10. Riddell SR, Elliot M, Lewinsohn DA et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2:216-23.
11. Klump H, Schiedlmeier B, Vogt B et al. Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategy. Gene Ther 2001;8:811-7.
12. Clackson T, Yang W, Rozamus LW et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci USA 1998;95:10437-42.
13. Fan L, Freeman KW, Khan T et al. Improved artificial death switches based on caspases and FADD. Hum Gene Ther 1999;10:2273-85.
14. Thomis DC, Marktel S, Bonini C et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001;97:1249-57.
15. Spencer DM, Belshaw PJ, Chen L et al. Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. Curr Biol 1996;6:839-47.
16. Iuliucci JD, Oliver SD, Morley S et al. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol 2001;41:870-9.
17. Introna M, Barbui AM, Bambacioni F et al. Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther 2000;11:611-20.
18. Ferrand C, Robinet E, Contassot E et al. Retrovirus-mediated gene transfer in primary T lymphocytes: Influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire. Hum Gene Ther 2000;11:1151-64.
19. Sauce D, Bodinier M, Garin M et al. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 2002;99:1165-73.
20. Berger C, Blau CA, Clackson T et al. CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy. Blood 2003;101:476-84.
21. Li Z, Dullmann J, Schiedlmeier B et al. Murine leukemia induced by retroviral gene marking. Science 2002;296:497.
22. Rosenzweig M, Connole M, Glickman R et al. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells. Blood 2001;97:1951-9.
23. Maus MV, Thomas AK, Leonard DG et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002;20:143-8.